Ohio’s (NASDAQ:PKOH) Q2 CY2026: Strong Sales, Full

Park-Ohio (NASDAQ:PKOH) reported Q2 CY2026 revenue of $440.1 million, up 10% year on year and 3% above Wall Street estimates. Full-year revenue guidance was $1.72 billion at the midpoint, about 1.1% above analysts’ forecasts. Non-GAAP EPS was $0.93, 15.3% above consensus; shares were about $41.53 after results.

Original reporting
Published Aug 5, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ohio’s (NASDAQ:PKOH) Q2 CY2026: Strong Sales, Full — source image
Decision brief

The 30-second read

$PKOHBullishMed
01

Why it matters

The key tradable items are the Q2 revenue and adjusted EPS beats versus estimates and the slightly above-consensus full-year revenue guidance midpoint, which can shift near-term expectations and positioning.

02

Market read

A company-specific earnings and guidance beat for PKOH with quantified figures, but with caveats around longer-term growth and margin profile.

03

What to watch

The guidance beat is only 1.1% at the midpoint, and the stock is described as flat immediately after results, suggesting the market may already have priced in part of the upside.

Relevance 8/10Novelty 7/10Timing: after-hours/late-day report on 2026-08-05

Background

Park-Ohio is a diversified manufacturing and supply chain services provider based in Cleveland, reporting Q2 CY2026 results and full-year guidance.

Company-level read

Ticker impact

$PKOHBullishMedium confidence
Context

Park-Ohio reported Q2 CY2026 sales of $440.1M (+10% YoY) and adjusted EPS of $0.93, beating revenue and EPS expectations.

Expected impact

Likely supportive for PKOH shares near term, with follow-through dependent on whether the modest guidance outperformance translates into sustained margin and EPS growth.

Evidence & confidence

The article provides concrete Q2 results (revenue, adjusted EPS) and a midpoint full-year revenue guidance figure above consensus, which are direct drivers for re-rating. However, it also notes weaker multi-year revenue growth and flat operating margin this quarter, limiting conviction.

Market effects

Signals modest demand resilience in industrial supply chain and components, but margin remains low versus typical industrial benchmarks.

Limited, as the disclosure is company-specific with no broader regional macro/regulatory catalyst.

Low, no international expansion, trade, or commodity input shocks are disclosed.

Counterpoint

Despite the beat, the article highlights sluggish multi-year revenue growth and flat operating margin this quarter, implying the outperformance may be cyclical rather than structural.

Key entities

  • Park-Ohio

    Reported Q2 CY2026 sales and adjusted EPS, and provided full-year revenue guidance.

  • Wall Street analysts

    Provided the revenue and EPS consensus expectations referenced in the article.

Related articles

$PKOHHigh

PARK OHIO HOLDINGS CORP (PKOH): Results of Operations and Financial Condition

PARK OHIO HOLDINGS CORP (PKOH) filed an SEC Form 8-K — Results of Operations and Financial Condition. ParkOhio Announces Record Sales and Strong Second Quarter 2026 Results; Raises FY 2026 Outlook CLEVELAND, OHIO, August 5, 2026 — Park-Ohio Holdings Corp. (NASDAQ: PKOH) today announced its results for the second quarter of 2026. “We are pleased to announce record second quarter r

$NVOHighAI 8/10

Novo Nordisk shares fall by up to 7% in Denmark — CNBC

Novo Nordisk shares dropped 7% in early trading on September 21, 2026, after the company announced new growth targets for its obesity treatment drugs. The firm aims to launch over five potential multi-blockbuster drugs by 2030 and expects sales of over 150 billion Danish kroner ($23 billion) by 2035. Novo Nordisk also anticipates matching industry revenue growth rates from 2026 to 2030.

$TCOMMed

Citi is bullish on these 2 Chinese travel stocks heading into the autumn holidays

Citi reiterated Buy ratings on Tongcheng (THG) and Trip.com (TCOM), citing attractive valuations and upcoming holidays as potential catalysts. Tongcheng reported Q2 2026 revenue of RMB 5.0 billion and net profit of RMB 851 million. Trip.com faces near-term headwinds but is expected to outperform in 2027. Analysts adjusted TCOM's price target to $60, maintaining Buy ratings.